NNZ-2591
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pitt Hopkins Syndrome
Conditions
Pitt Hopkins Syndrome
Trial Timeline
Oct 14, 2022 → May 3, 2024
NCT ID
NCT05025332About NNZ-2591
NNZ-2591 is a phase 2 stage product being developed by Neuren Pharmaceuticals for Pitt Hopkins Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05025332. Target conditions include Pitt Hopkins Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05879614 | Phase 2 | Withdrawn |
| NCT05025332 | Phase 2 | Completed |
| NCT05025241 | Phase 2 | Completed |
| NCT05011851 | Phase 2 | Completed |